Accession Number:

AD1094543

Title:

Therapeutic Benefit of Hsp90 Inhibition in Pulmonary Fibrosis

Descriptive Note:

Technical Report,30 Sep 2017,29 Sep 2018

Corporate Author:

Childrens Hospital Medical Center Cincinnati United States

Personal Author(s):

Report Date:

2018-10-01

Pagination or Media Count:

16.0

Abstract:

IPF is a fatal fibrotic lung disease associated with aberrant activation of fibroblasts and progressive fibrosis. The pirfenidone therapy for IPF has been shown to slow the rate of decline in lung function but do not halt ongoing fibrosis. This application will test whether inhibition of HSP90 activity, coupled with antifibrotic therapy of pirfenidone, will attenuate WT1-driven fibroblast activation. The proposed studies will provide robust, highly novel observations to rapidly pursue the long-term goal Translational exploration of the molecular mechanisms by which HSP90 activity positively regulates IPF pathogenesis in order to devise novel preventive and therapeutic strategies for IPF

Subject Categories:

  • Medicine and Medical Research

Distribution Statement:

APPROVED FOR PUBLIC RELEASE